Choisissez votre langue

Search

Renseignements

Aucune correspondance

Services

Aucune correspondance

Secteurs d’activité

Aucune correspondance

Personnes

Aucune correspondance

Renseignements

Aucune correspondance

Services

Aucune correspondance

Personnes

Aucune correspondance

Secteurs d’activité

Aucune correspondance

La vague Delta et les répercussions sur une réouverture

 

Le 28 septembre, BMO a réuni une table ronde pour faire le point sur l’état actuel de la pandémie et sur ses répercussions pour les marchés et l’économie. Les spécialistes ont discuté de l’évolution des cas d’infection, de l’hésitation vaccinale, des doses de rappel et de la façon dont l’économie et les marchés se comportent dans un contexte de pandémie qui perdure.


Écouter la discussion complète

La transcription sera téléchargée sous peu.

Le balado Faits saillants COVID-19 de BMO est diffusé en direct sur toutes les grandes plateformes, dont Apple, Google et Spotify.

Ce balado est en anglais seulement.


Ont pris part à la table ronde :

  • David Casper, Chef de la direction États-Unis, BMO Groupe financier

  • Dr Paul Casey, Médecin hygiéniste en chef, Rush University Medical Center

  • Angelique Richard, PhD, IA, Vice-présidente principale, Chef des soins infirmiers – Activités hospitalières, Rush University Medical Center

  • Brian Belski, Stratège en chef – Placements, BMO Marchés des capitaux

  • Margaret Kerins, Chef, Stratégie macroéconomique, Titres à revenu fixe, BMO Marchés des capitaux

 


Faire le suivi de la quatrième vague de la pandémie de COVID-19 : rencontre d’experts de BMO

Les enfants retournent à l’école aux États-Unis et au Canada, mais déjà la quatrième vague de la pandémie de COVID-19 jette une ombre sur le chemin vers la reprise. Au moment où les prévisions de croissance économique commencent à se faire plus modérées et où les marchés deviennent plus volatils, BMO a tenu une rencontre virtuelle avec des experts internes et externes pour prendre le pouls de ce nouveau développement dans la pandémie, et de son incidence sur la santé, sur les marchés et sur l’économie.

Animée par David Casper, chef de la direction États-Unis, BMO Groupe financier, la table ronde rassemblait des experts médicaux externes, à savoir le Dr Paul Casey, médecin hygiéniste en chef, et Angelique Richard, vice-présidente principale, Chef des soins infirmiers – Activités hospitalières, tous deux œuvrant au Rush University Medical Center (Rush), et, en ce qui concerne l’économie et les marchés, le stratège en chef, Placements, BMO Marchés des capitaux, Brian Belski, et la chef, Macrostratégies, Titres à revenu fixe, devises et marchandises de BMO, Margaret Kerins.

« Les expertises que nous avons aujourd’hui sont très bien équilibrées, a déclaré David Casper en ouverture de l’événement, en soulignant les récents partenariats entre BMO et Rush. Dernièrement, BMO et Rush ont collaboré de différentes façons, y compris lors du récent lancement du Rush BMO Institute for Health Equity, et c’est formidable de voir notre partenariat continuer de fleurir. »

Flambée du variant Delta

Même si la flambée du variant Delta se poursuit aux États-Unis – au moment de la rencontre, on comptait encore beaucoup plus de 100 000 cas quotidiens et plus de 2 000 décès quotidiens en raison de la COVID-19 à l’échelle du pays –, le Dr Casey a déclaré que les autorités médicales commencent à observer une baisse dans la courbe des infections, un signe encourageant malgré la nature imprévisible de la propagation du virus.

Comme seulement 55 % des Américains admissibles sont entièrement vaccinés, il existe une corrélation directe entre les foyers d’infection et le taux de vaccination. « Lorsqu’on regarde la carte des points chauds à l’échelle du pays ou qu’on cible les endroits où il y a encore des cas, on constate que c’est vraiment inversement proportionnel au taux de vaccination », a déclaré le Dr Casey.

Cela s’explique en grande partie par la réticence persistante à l’égard du vaccin. Angelique Richard a indiqué que la peur, le manque d’information, les mythes et les mensonges au sujet du virus et du vaccin ainsi que la méfiance à l’égard du système de soins de santé sont autant de facteurs contribuant à la situation.

Parmi les conséquences de cette hésitation, a poursuivi Mme Richard, il n’y a pas que l’augmentation du nombre de cas, mais aussi une augmentation du nombre de décès attribuables au virus et des répercussions multiples sur le système de soins de santé.

« C’est une situation de crise, a-t-elle dit. Le nombre de lits est limité et nous faisons face à une pénurie de main-d’œuvre; certains établissements de soins de santé ont vu leur viabilité financière et leur rendement être compromis. On ne peut évidemment omettre de parler des problèmes d’accès ou des restrictions qui ont ou qui avaient cours dans certains établissements, pour les patients qui, sans avoir la COVID-19, ont besoin de soins de santé. »

En ce qui concerne la vaccination obligatoire en entreprise, Mme Richard a dit que les organisations doivent avoir un pouvoir décisionnel à ce propos, et qu’elles doivent communiquer ces décisions de manière plus efficace à leurs employés.

« Maintenant plus que jamais, il faut faire preuve de leadership courageux », a-t-elle dit, invitant les dirigeants d’entreprise à prendre le temps de comprendre, d’écouter et d’éduquer les employés qui sont préoccupés par les vaccins.

Une approche locale, qui intègre des partenariats avec des leaders communautaires et des personnes de confiance clés qui peuvent être les têtes d’affiche d’une campagne de sensibilisation ou communiquer personnellement avec les gens, n’est qu’une seule des façons de mieux joindre le personnel. « Faites-en une affaire personnelle », a déclaré Mme Richard.

Nos experts ont également abordé le débat sur la COVID-19 de longue durée et les symptômes qui peuvent persister après que l’infection initiale s’est estompée. Pour le Dr Casey, les connaissances scientifiques sur ce qu’on appelle la « COVID-19 de longue durée » sont encore embryonnaires, mais il a dit qu’il observe un certain nombre de symptômes dans le système hospitalier : toux persistante, fatigue importante, confusion ou diminution de la fonction cognitive et maux de tête.

« Nous avons eu quelques personnes en très bonne santé de 30 ans qui disent qu’elles peinent à marcher de leur voiture à leur lieu de travail », a-t-il dit, en soulignant que ces types de symptômes à long terme sont rares pour d’autres types de maladies courantes.

L’économie : avoir confiance dans le marché haussier

En ce qui a trait à l’économie, Brian Belski, stratège en chef, Placements, a déclaré que la résilience dont ont fait preuve les économies canadienne et américaine, particulièrement en étant capables de changer de cap en tant que société et en tant que marché face à la pandémie, est ce qui le rend certain que nous n’en sommes qu’à mi-chemin d’un marché haussier de 25 ans qui a commencé en 2009.

« Je fais confiance à l’économie et au marché boursier américains, ainsi qu’à l’économie et au marché boursier canadiens, et c’est cette confiance qui nous permet de nourrir notre perspective optimiste, a-t-il déclaré dans son allocution d’ouverture. Cela témoigne vraiment de la solidité du marché boursier et des sociétés, du côté tant américain que canadien, et nous devons commencer à croire en ces capacités. »

M. Belski a fait référence aux craintes inflationnistes et aux signaux récents de la Réserve fédérale américaine (Fed) laissant présager une réduction des mesures de relance avant la fin de l’année et a maintenu son point de vue selon lequel les problèmes d’inflation sont temporaires (probablement un ou deux trimestres) et des hausses de taux d’intérêt ne devraient se produire que vers la fin de l’année prochaine.

La proposition de valeur du Canada

Se fondant sur les prévisions actuelles de croissance du PIB de 5 % au Canada et de 5,8 % aux États-Unis, M. Belski a déclaré que de nombreux investisseurs passent à côté de la proposition de valeur des marchés canadiens, qui, selon lui, sont sur le point de surpasser leurs équivalents des États-Unis, si l’on en croit les bénéfices et les flux de trésorerie « extraordinaires » des sociétés.

« Selon nous, le Canada continuera de surpasser les États-Unis au quatrième trimestre et pour une bonne partie de 2022, grâce aux grosses pointures des secteurs des services financiers, des matières premières, de la consommation discrétionnaire et de l’industrie, secteurs qui continueront, selon moi, de produire des rendements supérieurs, a-t-il dit. Nous surpondérons les mêmes secteurs aux États-Unis. »

M. Belski a recommandé une approche équilibrée croissance-valeur dans les deux marchés.

Il s’est également prononcé sur les perspectives sur trois à cinq ans : « Nous continuons de croire que le marché boursier atteindra un taux croissance annuelle composée de 13 % à 15 % au cours des cinq prochaines années, voire des dix prochaines années, et nos secteurs de prédilection sont de loin les technologies, les services de communications et la consommation discrétionnaire. »

Titres à revenu fixe, devises et marchandises et rhétorique de la Réserve fédérale

Margaret Kerins, chef, Macrostratégies, Titres à revenu fixe, devises et marchandises, BMO Marchés des capitaux, a déclaré que, même si elle se maintient du côté de ceux qui croient que l’inflation est temporaire, un changement dans la rhétorique de la Réserve fédérale au sujet de la réduction des mesures de relance est déjà prévu plus tôt que tard sur les marchés.

Selon Mme Kerins, des annonces récentes de la Fed laissent entendre que les décideurs « ne laisseront pas l’inflation s’emballer trop longtemps ». Cela survient une semaine après la réunion de septembre de la Fed, qui a renforcé le fait que le seuil nécessaire à la réduction des achats d’actifs avait été atteint en ce qui concerne l’inflation, et qu’il était sur le point de l’être du côté de l’emploi.

Elle a déclaré que selon le plus récent changement de ton, la réduction des mesures de relance serait à prévoir dès novembre ou décembre, lorsque la Fed diminuera ses achats de 15 milliards de dollars par mois; elle s’attend à ce que s’ensuivent des hausses de taux d’intérêt à la fin de l’année prochaine.

« Nous considérons que la réduction des mesures de relance est imminente », a-t-elle dit, mais cela ne signifie pas que la croissance économique sera paralysée. « Nous envisageons le tout comme une réduction des facteurs favorables à l’économie, a déclaré Mme Kerins. Lorsque la Fed commence à resserrer sa politique, cela devient en fait un facteur défavorable. »

En raison des tendances démographiques à long terme et des changements technologiques dans l’économie qui continueront d’exercer des pressions sur l’emploi, Mme Kerins a déclaré que même lorsque les taux commenceront à augmenter, ils resteront probablement relativement bas par rapport aux niveaux historiques.

Cependant, le contexte continuera d’évoluer et, avec lui, l’orientation de la Fed, selon Mme Kerins. Les changements à venir dans la composition de la Réserve fédérale américaine, par exemple, pourraient mener à une approche plus conciliante, voire repousser le resserrement jusqu’en 2023.

« Un an, c’est long sur les marchés, même pour les prévisions, donc les données doivent évoluer comme la Fed s’y attend pour qu’elle relève les taux », a-t-elle dit.

Mme Kerins a déclaré que l’an prochain, un nombre record de coupons du Trésor seront mis à la disposition des marchés privés – environ 2 000 milliards de dollars par rapport à 1 800 milliards de dollars en 2021 et à -443 milliards de dollars en 2020 –, mais elle prévoit que ces émissions importantes seront attendues par une forte demande mondiale, avec le contexte des variants du virus.

Bien que la COVID-19 continue de jeter une ombre sur notre chemin vers la reprise, il y a des raisons de faire preuve d’optimisme « prudent ». Nos experts médicaux nous ont assurés qu’ils étaient optimistes, en raison des progrès que nous avons réalisés au cours des 18 derniers mois pour comprendre ce virus, mais qu’ils faisaient preuve de prudence, car chaque nouvelle infection offre une autre occasion au virus de muter vers des formes plus dangereuses.

Comme le Dr Casey l’a déclaré : « Il ne s’agit pas d’un effort des États-Unis ou du Canada, mais bien d’un effort mondial visant à élargir la couverture vaccinale de manière à pouvoir éviter d’autres variants. »

« C’est une période difficile pour nous tous en tant que leaders, a conclu M. Casper. Nous voulons que l’économie continue de progresser dans la bonne direction. »

LIRE LA SUITE

 Disponible en anglais seulement.

DAVE CASPER: My name is Dave Casper. I'm the U.S. CEO for BMO. Thanks for joining us on what I think will be a very important conversation. We have a great balance of expertise on this call today. Two very well-respected medical professionals here in Chicago, Dr. Paul Casey, the chief medical officer at rush university medical center and Angelique Richard, the senior vice president of hospital operations and the chief nursing officer at Rush. Thanks to both of them for their time. Many of you may not know this, but BMO and rush have had a great partnership over many years. It's taken different shapes including recent launch of what we're very proud of, the rush-BMO institute for health equity. It's a great chance to see our partnership grow and help improve the equity here in Chicago. We also have superstars with BMO capital markets. Brian Belski and Margaret Kerins. Brian will speak on how the look at the economy and the markets today, how they have trended throughout the pandemic and factors that may impact where the economy and the markets will go from here. Margaret will provide an update on the federal reserve and the treasury. Lots to talk about there. To our customers on the call, thanks for your business and putting your trust in BMO and taking your time to join us for what I'm hoping will be a lively an informative discussion. We'll have questions at the end and you can submit the questions during the call by typing them in to the chat at the bottom of your screen. Before we begin, I want to put the disclaimer on that the contents of what you hear are for information purposes. Please see and consult your physician if you have health questions. We have great sources here today. So let's start with our good friends from Rush. First to Dr. Casey. Hello, Paul and Angelique. Good morning. >> Good morning. Thanks for having us. >> So Paul, first question to you. Give us an update. Where do we stand on the pandemic especially now that we have variants and as kids return to school, people go back to work.

DR. PAUL CASEY: Thanks for all that have joins and the continued partnership with BMO Harris and the joint work around health equity. Certainly no surprise to anyone that we're still well in the midst of the pandemic. Although we are beginning to see the downward slope of the delta variant that is really caused the surge of cases since about mid July where it became the predominant strain throughout the United States and prior to that had of course gone through Europe as well as India. So that's encouraging that we are seeing cases go down in most places throughout the country. I think the other thing that is important to note is when one looks at the map of hot spots or places where there's case, it's inversely proportionate to the vaccination rate in those areas. That's no surprise with what we know about the vaccine efficacy that we continue to see a number of hot spots pop up where there just hasn't been that level of uptick as we like with the vaccination. So again, one thing we learned about this pandemic is that it's inherently unpredictable. That being said, we closely trend the cases throughout the country and certainly here in Chicago and we're encouraged by what we've seen the last week or two.

DAVE CASPER: Paul, question: Because we're a North American bank, I was just down the hall with my Canadian colleagues that are here in the U.S. today. They are just about at 80% of double vax of those eligible. Where do we stand in some of the real hot spots on that? Also, give us an update on the booster as well.

DR. PAUL CASEY: Absolutely. The vaccine uptake here in the United States has been quite variable. There are areas -- overall when you look at the United States on a whole, it's about 55% of eligible Americans that have been vaccinated, fully vaccinated and 64% of Americans that have had at least one vaccine. Now, that also varies quite a bit by age group. The good news there is it's about 83% of those over 65 that are fully vaccinated and 94 that have received one vaccination. That is certainly the most at risk group for it as well. So we still see the trend as well in terms of the vaccination rate. Can tell you here in Chicago where we closely track the hospitalizations, 99% of the patients that we see that are hospitalized are unvaccinated. That's really the case throughout the United States. I'm sure other countries throughout the world is that the hospitalizations are being driven by the unvaccinated. Where we see in the news, you know, states and cities overwhelmed and have no more icu capacity, those are the states and cities where the vaccinate rate is quite low. In terms of the vaccine boosters, obviously a lot of that news is just emerging. Like any vaccine we've seen the -- the science is telling us what we expected with the vaccine, that over time the immunity would wane somewhat and that's the case for the vast majority of vaccines. We're seeing the data is really supporting that is most pronounced in those that are over 60 or 65 years old. That was a study out of Israel that helped the CDC to guide that decision because they've been following this closely. Looks like that waning immunity starts around six months after the second dose of the vaccine. So thus the recommendations of the CDC advisory panel to do a booster vaccine after six months for those over 65 or those high risk as the CDC director Rochelle Walensky put forward, people in high risk exposure are also recommended to get that booster vaccine. So something that we've certainly got a lot of questions about here at Rush and we made plans to roll that out throughout the city as well.

DAVE CASPER: Angelique, as we all know, there's a lot of people still for their own personal reasons are deciding not to get the vaccination. Can you give us your insights, explain the hesitancy and the ramifications of this.

ANGELIQUE RICHARD: Sure, Dave. I too want to thank BMO for having this. I think doing this is one of the most important things that we can do for our employees and quite frankly at large. There's multiple reasons for hesitancy. There's fear, lack of information, a knowledge deficit, there's myths and untruths about the virus as well as the vaccine. And there's mistrust among some around the vaccine as well as in some cases healthcare as a whole. I think the ramifications and the consequences of this are what we're seeing. This increase in cases, the growing numbers in different parts of the country of covid cases, opportunities for there to be further virus variants. As Dr. Casey mentioned, states where you're seeing the highest number of cases strong correlations with the lowest number of vaccine rates. Obviously the worst consequence is growing deaths from the virus.

DAVE CASPER: So Angelique, what is this doing -- what is he hesitancy doing to the healthcare system and healthcare professionals? We all woke up to see what's going on in New York City where firing healthcare professionals if they haven't been vaccinated. So you can take this question anywhere, but I'd love to hear the impact not only in Rush but in general.

ANGELIQUE RICHARD: It's going many places. I think this has truly been one of the most difficult challenges in healthcare. Certainly in my lifetime in many cases at many organizations. It's at a crisis level. So there are multiple strains and stressors on the healthcare system. There's shortages as you just described of healthcare staff that are either a result of the taking deposition on and mandating vaccines or because of the pandemic itself. There's limited bed capacities and work force deficits. You hear a lot about nurses on the news but there's food and nutrition workers and transporters and security staff, respiratory therapists. Those are some of the key challenges that healthcare systems are having from a work force perspective. There's supply and equipment challenges and deficits. There's a strain -- been a strain on the financial viability of healthcare and the limitation of services at different points in this pandemic such as surgical elective cases has also been a challenge. Thens will just the access and limitation again that many healthcare organizations have either gone through or going through for patients with noncovid healthcare needs. Somewhat in competition with patients who have covid. So they're I having for the same resources and the same beds. So it has been a real challenge and a real strain on healthcare organizations across the country.

DAVE CASPER: Thanks. We see it everywhere. So Paul, back to you. So a large number of our population have had covid now. And some have had it for, you know a year or more. What are we seeing, what is the science telling us about the long-term effects of those that have had covid regardless of whether it was a mild case or more severe. I'd love to hear that and our audience would as well.

DR. PAUL CASEY: A great question. Thanks T honest answer is the science is still emerges on this. We're participating in a large CDC trial around long hauler syndrome and what those symptoms are. We have a multidisciplinary clinic here. I can tell you the symptoms that we're hearing from those that are at that clinic really tend to be persistence of a cough, really fatigue to the point that we've had a few young very healthy 30-year-old individuals that say they can barely walk from their car in to work and they also complain of this persistent brain fog or difficulty with the same cognitive ability. Headaches are common. As well as really myalgias, muscle aches. This rarely happens with other common viruses, certainly cold viruses, flu viruses. There's a few sequelae, but we're seeing a higher incidence of these persistent effects with covid. So that's something that we're keeping an eye on and something that the science will continue to emerge on but it's not a small number of the population that ends up with some sequelae lasting anywhere from weeks to months.

DAVE CASPER: Science that says that if you have been vaccinated and you have covid, whether that will make any difference in the long-term effects?

DR. PAUL CASEY: That is really a key question. I don't think we have the data necessarily now to actually answer that. I think the feeling from what we're seeing early on and I think the data will support that the vaccine is very effective in decreasing the burden of the virus both the actual amount of virus that one is infected with as well as the long-term effects. So what we're seeing within the -- our long-hauler clinic is those that are unvaccinated, have accounted for 99.9% of the cases we're seeing there. So I think the science will support that as that data emerges.

DAVE CASPER: Thanks. Angelique, all of us that are running businesses or managing businesses are, I think, you know, all questioning our decisions, what we can do, what we can't do. I'll see at BMO we've said we've no longer made it optional to tell us whether you're vaccinated or not. Everybody has to tell us. That's mandatory. They either are vaccinated or expect to be or they're not or they'll tell us it's none of your business. We have said for those in category 2 or 3, if your job requires you to come to work, we need to have you tested at least twice a week. That's going into implementation today. So that's not all the way to a mandate, but it's pretty close. I'd love your ideas. What should we be doing, what can we do, what would you suggest to all of us in businesses what is the best route to take to nip this in the bid as much as possible?

ANGELIQUE RICHARD: Let me first start by saying, you know, I think courageous leadership is needed now more than ever. So I certainly applaud you and your team for making those really tough decisions. We've had to make similar ones. So I can appreciate the discernment that goes into that. You know, I think there's -- here's the good news. There's a lot that can happen and that we can do as it relates to our staff, our employees. I think, you know, this sounds very basic but it is. I think we need to seek first to understand where people are at. I think we need to listen and educate individuals because there's so many as I said earlier, so many myths and untruths and that they're hearing in their communities as well as on the news. I think in many ways a grass root approach is the best approach in particular with those that are struggling with this decision. You know, they're in a tough position as well trying to make this decision and in many cases, you know, determine if they're going to be able to work. So I think that, you know, this requires partnerships and mobilization of key trusted individuals and whether those are -- you know, we have partnered with community, religious leaders within the community. This also means, you know, key and trusted individuals within your organization. Maybe individuals that look like or have similarities to individuals that are struggling with this decision. It would be helpful to them. Sports heros. We did a huge campaign with them because we recognize the importance that they have in various communities, town halls like this, small groups, a peer-to-peer approach and personal stories. I'll share one of those personal stories. My doorman for over 20 years had really struggled with the decision of getting the vaccine. I think I had been talking to him since December up until we successfully got he and his teenage son vaccinated. It took every day having a conversation about this, took listening, understanding to what his fears were. Really what pushed him over the edge was understanding that he trusted me, right? I'm a healthcare provider, I'm a nurse. And offering to give he and his son the vaccine myself. And we -- it was probably -- I probably was more excited and happy about that than I was my own vaccine. So that's kind of what I mean about this, you know, make it personal. These are employees, our greatest assets. And really getting to that kind of grass roots level with them to help them to -- through this discernment and decision. That's some ideas, Dave.

DAVE CASPER: It's a great story. I'll tell you, I think we've all learned to kind of check our judgment Gene in our drawer before we come in to work and listening. Everybody has a story. It's easy to say how can you be so stupid. That's the wrong approach. You may get a few people asking for house calls. We probably all know a few people that can use your magic touch.

ANGELIQUE RICHARD: Happy to do it.

DAVE CASPER: So last question is for you, Paul. I'm an optimist. Our next speaker, Brian, is the ultimate optimist in a good way. Tell us -- give us some hope as to why we should be optimistic, where we are in the virus and the pandemic. If that's the wrong question, you can take me down the other way and tell me why I shouldn't be so optimistic. Didn't mean to lead the witness.

DR. PAUL CASEY: No, absolutely. I think Angelique and I fall in the optimism camp around here as well. So I would say, you know, we're also cautiously optimistic. Look 18 months ago. We didn't know the symptoms, how I'd spread, didn't have any treatments, certainly didn't have a preventative treatment like a vaccine. We've come an incredibly long way and that's reason for optimism. We know so much more about the virus in every single way that we can. We know how to prevent the spread if virus effectively. It's getting people over the hump. I say we add the cautiously piece because every new covid infection allows the virus the opportunity to mutate and create a new variant. That's why we closely track the variants of concern across the world. Because really it's going to take -- this isn't a U.S. effort or Canadian effort. It's a global effort to get the vaccine levels to where they need to be in order to prevent the emergence of variants and the concern there is that there may be a variant that could ebb investigate the anti-bodies generated by the vaccine. That is something that we need to continue to keep a close eye on.

DAVE CASPER: Okay. I'm feeling better. So Dr Casey and Angelique, can't thank you enough for all the work you do at Rush and for all of our communities. Thank you. Keep it up. I appreciate it. We're now going to turn things over to our BMO capital markets side. Our first speaker is my very good friend, our chief investment strategist, Brian Belski. Brian is going to talk to us about what he sees in the markets and how all of what we've heard and all of what we know will have an impact on the economy going forward. Over to you, Brian. Thanks again, Paul and Angelique.

BRIAN BELSKI: Thank you, Dave. I'm humbled to be sharing this with you. This is my 18th or 19th covid call that we've done for clients. I'm struck by Paul and Angelique and how clear, concise and complete they have been with their comments. Angelique made an awesome comment with respect to myths and untruth. Many of you know that I'm a myth and untruth buster. I state the truth and have faith. I have faith in the U.S. economy and stock market and in the Canadian economy and stock market. That's what's kept us so bullish. So at the end of my comments, we'll talk about our forecasts with respect to what all of this fun stuff means with the fed, the economy and the stock market. People have to step back and pat themselves on the back and really understand that the transition and the pivot that we made as a society and a marketplace is unbelievable. Speaks to the strength of the United States stock market, our companies and the Canadian stock market and our companies. We have to believe that. I'm going to steal Angeliques myth and untrust and talk about that in a bit. Margaret Kerins is going to talk about interest rates much more eloquently. Let's talk about the fed, what that means for the economy and some political things going on obviously in Canada and now the U.S. especially this week and what it means for your money. First off on the fed, the top of the house view is that the fed is most likely not raising rates for a while yet. The taper talk, which now is kitchen table type fodder much like quantitative easing was, in fact, back in 2007, 2008, we didn't know what quantitative easing was. We had to look it up like what taper was. For perspective, we've had one official tapener the history of the fed. Seems like the market and the economy is too fixated on the taper. Be that as it may, I think the key thing from the fed's perspective, they've been accessibly communicative. We're living in an age and society that we want to know everything right away. Mr. Paul has done a good job in terms of laying the ground work for eventually raising rates. He's been a little bit more ambiguous with respect to his data raising of rates but clear he's going to talk about tapering in November and then really start doing the tapers in December. That's the house view. I think it's consensus as well. So the market likes this. That we seem to have the same type of messaging from the fed in consistent messaging from the fed with respect to interest rates. In terms of inflation, the fed has been very clear that they continue to believe it's transitory. Seems to me that everybody kind of forgets that the smartest person in the room is the fed followed by the stock market. They flip back and forth. We seem to be debating this transitory inflation issue. We're going to go with the fed T house view is to go with the fed and what they're saying with this. There's a lot of talk with respect to bottle necks and the like and we continue to believe this is still a quarter or two effect with respect to inflation T key metric that many people are forgetting with respect to Mr. Paul is that last August at Jackson hole, he changed the mandate away from inflation and toward employment. If you read his statement last week, the first thing he talked about is employment. That remains the quandary and get to a sub 4% employment, which treasury secretary yellen points to with respect to the Biden administration. So I don't think there's an easy answer when the fed will raise rates. Looks like it's well into 2022. But what does that mean for growth? If you take a look at where GDP is in the forecast, we're forecasting 5.8% and 5.8% in Canada. What is interesting, we have a drop off in the U.S. going down to 3.5% GDP. Canada will surpass the United States next year by about 100 basis points with respect to GDP. I don't think anybody is talking about that. I think that really sets up Canada to do quite well in the fourth quarter, which is our call to outperform from a economic perspective but from a stock market perspective. I really think that Canada's fortunes are tied to the United States with respect to cross-border relationship, but many investors around the world need to start thinking more about Canada. On to politics, which you heard me speak before, we continue to believe that investors give politicians too much credit. Politics we have proven has nothing to do with the absolute performance of the stock market. It's about the trajectory of what happens. I think too -- let's use Angeliques I have no original thoughts so let's talk about myths and untruths. I'll harken back to the fourth quarter following the U.S. election. The first quarter following when the blue wave happened and it happened for real. There were a lot of fears that the full blown democratic government would derail the market. That didn't happen. We're up 20% this year. GDP continues to grow. I think there's too much assumption with respect to giving those politicians too much credit on to what will happen this week with the budget battle. We continue to believe it's the house view that they'll put some sort of patch work deal together to keep the government open. It's easier for president Biden to do that relative to other presidents especially given full control of congress. The infrastructure bill and even too is the taxes situation. So you go back to the beginning of the year and think about the myths and the untruths on what would happen on the political front. Let's not give politicians as much credit as the media and we're afraid of. Let's focus on how strong we are as an economy and how strong as a stock market. We've gotten through this and proven it's not right to be fearful of what potential politicians could do. Speaking of politics, we had an important election in Canada. It's status quo. The liberals won. My friend Doug Porter wrote about it in terms of budgets T biggest province, Ontario, analysts are seeing a budget deficit of twice what it came out with. There's a resounding fear that we're spending too much money. I think that Canada from a bank of Canada perspective will continue to follow the fed with respect to what is happening in interest rates in the United States. The Canadian economy is doing quite well. Jobs are coming back. The key things is the housing side. Housing continueses to be very strong and lending there is very strong especially on the residential side. So let's talk about what to do with your money. We continue to be bullish as Dave said. We've been on record by saying the United States stock market has been in the 20 to 25 year bull market that started in 2009. I think much of this has been driven by excess speculation on the negative side. This year we were supposed to have a negative year T month of September was supposed to be bad. You had a lot of people that do from what I do calling for a 10 to 20% price correction meaning prices will go down. Funny thing happened. Prices are flat for the month of September. September is typically a more volatile month. However, it's this type of chicken little analysis that I think is more about grabbing headlines than driving fear than what is true. So what is true? Canadian stock market is doing a wonderful job in terms of earnings. In fact, the last couple months we've been writing about the earnings riverry in Canada and using adjectives like epic. That epic earnings growth is transitions into fantastic cash flow, which of course in Canada, which is very important, dividend growth. So we think Canada will continue to outpace the U.S. for the fourth quarter and well in to 2022 with the great financial companies, great material companies, great consumer discretionary companies and those areas that will continue to outperform. We're overweight the same sectors in the United States, those being financials, consumer discretionary, industrials, materials. We believe a balanced approach to investing being equal weight, growth and value is the best way to play it. We've had the ebbs and flows type market, growth stocks outperform and value is oversold and rallies back up again. Same thing with small, mid and large. That's why in the beginning of the year we said equal weight everything. It's been the right call. If you care to hear about a three to five-year outlook, we will provide one. We think the stock market will get 13 to 15 compounded growth over the next ten years and the favors sectors are technology, communication services and discretionary. We're good at buying stuff in America. What are we buying? We've proven more than ever during the pandemic with respect to the need and demand for more technology, more contents. Those trends are going to continues. Not just from a personal side by clearly from a manufacturing side as we depend more on robotics and more or bringing manufacturing capacity back to the United States. That leaves us at 4,800 for an S&P 500 target on $210 of earnings. The second time we revised our targets for the U.S. and Canada in a year. We rarely do that. I think that really speaks to our confidence with respect to what we're saying in stocks N Canada, we think all-time highs for the TSX at 22,000 and $1,400 of earnings. We love the cross border relationship on a fundamental basis. I'm going to hand the ball off to my very good friend, Margaret Kerins who is BMO capital markets head of fixed income currency around commodity strategy. Margaret?

MARGARET KERINS: Thanks, Brian. Thanks to everyone for joining us. Brian mentioned fed taper and pretreasury market pricing. I'm begin with that. Basically what has been happening is the treasury market has been pricing to the expectations of how the fed will react to inflation on the ground and future expectations for inflation. So what we thought earlier this year is the market pricing in inflation trade is we thought the fed would wait to taper and lift-off would be a few years out. At that point, the high was reached around 174. Since then, what we've had is the fed messaging that they were not willing to let inflation run hot for too long in order to reach the employment mandate, which includes an inclusive employment as well as full employment. So basically earlier in the year, the market thought that inflagrants would run hot for quite a bit of time longer than the current pricing. So what we saw is rates peaked in March, late March and rallied back hard through the remaining course of the year up until the past few weeks where once again, the market is pushing rates higher so our view right now is that basically probably another 10 to 15 basis points to run before we see better buying coming in from the large institutional clients. We talk to large institutional clients every day. So this is what they're telling us. We actually think that rates will rally back down back to the 125 to 135 range by the end of the year. And then next year we will see a push higher, but not too much higher. Really looking for 175 to 2% in ten-year yields. Plus, what is critical next year and even now I think is a different story in the market is what will happen to five-year yields. Five-year yields should reflect the full tightening cycle. We pushed up past 1% today and we expect that pressure to continue through year end, probably reaching 110 to 115 and 140 by mid year next year. So again, we're expecting around 175 to 2 and to push up to 140 early next year. In terms of that taper, thatship is sailing as Brian mentioned. The fed is on pace to taper announcing as soon as November decreasing purchases by $15 billion in total per month. Over this period, will still purchase $280 billion in treasuries. The way we're thinking about tapering, it's a reduction in the tailwind pushing the economy forward. That is very different than a tightening cycle, which is a headwind. So the market is viewing the headwind -- you know what the headwind does. It will contain inflation. We know the fed has the tools to fight inflation and the market does in fact believe this and this is reflected in the long-term yieldses that we see today. So of course, when the fed does tighten, which is market is pricing for next year, we're are going to have some changes in the composition of the federal reserve board which could slant more dovish. A year is a long time in the markets, even for forecasts. So the data has to evolve as the Fed Ex pects. Probably about 3 points a year. Of course, you know, much more aggressive than we have seen in the last cycle. We started off with one for an entire year followed by 125 a year later. So depends on the evolution of the data. You know, we are in the inflagrants is transitory camp. We think that rates will remain relatively low historically. This is based on the longer term demographic trends, the technological changes in the economy that should continue to weigh on unemployment. We also have a part rate problem in the United States that will take time to work out in addition to the over-5.3 million below what they were in February of 2020. So this is going to take some time. We do think the curve of course is going to continue to flatten by 530. Interestingly, one thing to note is that we are expecting the U.S. department of treasury to begin cutting can you upon issuance as soon as November. Our projections are that they're about -- they would be 900 billion overfunded next year if they did not cut coupons. The 900 billion will be made up via bills as well as coupon cuts F you think about that, while the if Ed is slowing its purchases and the fed is cutting coupons, there's an offset to that. That said, the amount of treasury coupon debt that will be available to the public markets next year will be a record amount over $2 trillion. About $300 bill more than last year. Of course, when the site came out of the gates in March of 2020, the amount available for the public was negative 400 or 500 billion. Our expectation is that the coupon cuts will offset some of the decrease in treasury purchases. Another positive for the market that we should probably mention is that the fed will own and continue to own over $5 trillion in treasury. They will roll these over at auction. That is an enormous amount. They own 29% of treasury coupons outstanding. Even though we're decreasing this tail winds to the marketplace, the fact that they're still holding large balance of treasuries is quite positive. In addition to that they still will be buying 280 billion. Of course, when the fed does tighten, it does in fact become a headwind. One question that we are getting over and over again in these markets is about credit spread. Credit spread traded in about a ten-basis point range a year to date. They're near the post great financial crisis types right now. Many are asking, well, if the fed pushed everybody out, the risk curve, dooring QE, will that reverse once they slow QE down or start tightening? We think about this, think about last year alone. We had 1.7 trillion in treasuries available to the market. You know, corporate debt issuance was near record highs. On a net basis, that should come in around 400, $450 billion this year. Well below the over one trillion last year. Next year it will likely slow as interest rates rise a bit. Some of that will offset. We continue to expect I.G. credit spreads to remain near the post great financial type before coming under slight pressure next year. We're not expecting great big also in credit spreads. Moderately higher interest rates next year. Watching the five year sector and expect in the 175 to 2% range, which is probably quite a bit below the rest of the strait. Our interest rate call has been right the past several years. So with that, I'll will pass it back to Dave Casper. Thank you.

DAVE CASPER: Thank you, Margaret. Thank you, Brian. Great summary of what is going on. Okay. We have time for some questions. Some have submitted ahead of time and some have shown up already. So first question is to Paul. If I previously had covid 1, 3, 6 month ago, is the vaccine still necessary? How long after having covid to obtain the vaccine?

DR. PAUL CASEY: A great question. The recommendation around that is to wait until 90 days after having had covid for a vaccine. So importantly if you've had covid, that's not the equivalent of being vaccinated. So those that have been sick with covid still need to get vaccinated. But waiting that three month period will make sure that you don't have the -- you'll be covered through that period and not necessarily have the same reaction to the covid vaccine itself.

DAVE CASPER: Thanks. Next one is Paul. This could have been mine. If I had the Moderna vaccine, should I wait for the Moderna booster to come out?

DR. PAUL CASEY: Another great question. Yes, my advice is yes. The safest bet is to wait to be boosted with the same vaccine as your initial dose. That is in line with the CDC recommendation. The Moderna booster dosage should be approved we anticipate in the weeks ahead. Shouldn't be too long a wait. But the recommendation, if your initial series was with Pfizer, go with Pfizer. If your initial series was with Moderna, go with Moderna. That's the data available to know how effective those are.

DAVE CASPER: Thank you. Paul, allergies are bad right now. This could be mine, too. How would one differentiate between I have my usual allergies or whether or not I need to get covid tested?

DR. PAUL CASEY: Yeah, this is a tough one. I can tell you with three little boys at home, when one of them wakes up snotty, it changes from what we used to do a couple years ago about a common cold. You know, the advice around this is if you get seasonal allergies and you've always had seasonal allergies this time of year and it feels like the seasonal allergies, in all likelihood it's your seasonal allergies. If there's sometimes inconsistent with that, the safe bet is to get tested to be on the safe side. It's easyr fortunately to get the test and you can fairly rapidly get an antigen test that is followed up with a pcr as a confirmatory. That would be my advice.

DAVE CASPER: One for Brian or Margaret. What would a government shut down, what could of impact would that have on the markets and the economy and the likelihood of that as well.

BRIAN BELSKI: Ladies first, Margaret.

MARGARET KERINS: Thank you. We've seen this playbook so many times before. I think the best case is that breaching the debt ceiling, letting it go is not good for either political party with mid-term elections next year. Right now the Republicans and some of the more moderate Democrats want a lower fiscal package around holding the debt creeling to that. We think it will go down to the 11th hour but it will be resolved. Full government shut down, we've been through it. It's disruptive. But at the end of the day, we have seen the playbook before. The real implications for what's going on in the market, we have investors that can't risk buying anything surrounding those dates where the treasury might in fact run out of money. Even though we think it's a low probability, they shun those. Because they can't. They have to have that money. They can't get it three days later. So I think it's disruptive but the base case is it does resolve itself. We've been through this before. The last time they let it go, it was not good for either of them. Right?

BRIAN BELSKI: Yeah, we echo the same questions. Chairman Powell and secretary yellen are talking right now to congress. Really trying to push them to get this deal done. Per our comments, it echo what's Margaret said, they'll get the deal done. This is in 2011. The debt down grading of the United States. Let's not go back to the myths and untruths when this happens. Markets will rally when they feel better about this. The end of this week is the end of the calendar quarter, too. So you're probably going to see activity because of that.

DAVE CASPER: Can't wait. I feel we've been through a few times before. So Angelique, Brian, Margaret, Paul, I appreciate your time and I appreciate your honest and robust candid answers. To our clients on the call, thanks for joining us. Thanks for being clients and thanks for being perspective clients because you're not all clients yet. It's a tough time. It's challenging for all of us as business leaders and I want you to know that all of your BMO reps are with you and are available anyway we can be to help in many ways. If it's keeping the lights on in your operations, we can do that as well. But in all of the cases, we just want you to know we're here and we want to help and we want to get this economy continuing to move in the right direction. Thanks to everyone. There will be a recording on this call on our website for those that couldn't make it now. Thank you again. Thanks to all of our guests and to all of our listeners.

David Casper Chef de la direction États-Unis, BMO Groupe financier, président et chef de la direction
Brian Belski Stratège en chef des investissements
Margaret Kerins, CFA Chef - Stratégie macroéconomique Titres à revenu fixe

PARTIE 1

North American Investment Strategy: 2021 Market Outlook

Brian Belski 04 février 2021

  Disponible en anglais seulement. While 2020 has been a challenging year, it’s also highlighted our resilience and determination. T…


PARTIE 2

COVID-19 : La présidence Biden et ce à quoi s’attendre

Brian Belski, Michael Gregory, CFA, Margaret Kerins, CFA 26 janvier 2021

  Maintenant que Joe Biden a été assermenté comme 46e président des États-Unis et un an jour pour jour apr…


PARTIE 3

Gestion des flux de trésorerie de la prochaine génération : votre feuille de route de la transformation numérique

Marc-Andre Bergeron 09 février 2021

  La numérisation des paiements est plus importante que jamais, à mesure que les entreprises cherchent à augmenter leur …


PARTIE 4

Le grand saut dans la dette – Comment les détaillants ont emprunté pour rester à flot durant la COVID

Simeon Siegel, CFA 06 avril 2021

  Les détaillants sont plus nombreux à emprunter pendant la COVID que durant la crise financière mondiale  …


PARTIE 5

Le secteur minier et les facteurs ESG

Magali Gable 21 avril 2021

  Cette année, lors de notre 30e Congrès annuel mondial sur les mines et métaux, les producteurs se sont succ&eacut…


PARTIE 6

Évolution de la négociation aux États-Unis

Joe Wald 21 mai 2021

  Des modifications apportées à la règle 606(b), à la transparence et à la règle des donn&eac…


PARTIE 7

COVID-19 : Les 100 premiers jours de Joe Biden : vers la reprise

Dan Barclay 14 juin 2021

  Au terme des 100 premiers jours de Joe Biden à la Maison-Blanche, les experts prédisent un vif rebond économique …


PARTIE 8

IN Tune: Food and Ag Takeaways From the Farm to Market Conference

Joel Jackson, P.Eng., CFA, Kelly Bania, Kenneth B. Zaslow, CFA 02 juillet 2021

Disponible en anglais seulement IN Tune is a podcast featuring Equity Research analysts from BMO Capital Markets. Our episodes explore…


PARTIE 9

De formidables nouveaux facteurs donnent les moyens de croître aux activités de fusion et d’acquisition aux États-Unis

Lyle Wilpon 26 juillet 2021

Nous n’apprendrons rien à personne en affirmant que nous traversons actuellement l’un des marchés de fusions et acquisiti…


PARTIE 10

Accélérer la voie de la reprise

Dan Barclay 16 août 2021

  À quels obstacles pouvons-nous nous attendre et quels sont les risques? L’inflation entraînera-t-elle un changement de p…


PARTIE 12

Le meilleur des deux mondes : L’avenir du travail sur les marchés des capitaux

Dan Barclay, Aine O’Flynn 07 octobre 2021

  Jusqu’à tout récemment, l’argumentaire sur support papier faisait partie intégrante de l’arsenal des…




Autre contenu intéressant